Successful clinical trials followed by FDA approval of Polθ-i will bring hope to cancer patients with HR-deficient disease and to those patients that have acquired PARP-i resistance, a serious obstacle for this promising and newly developed class of therapeutics. The gene discussed is POLI; the disease is cancer.